The value of patient-centred registries in phase IV drug surveillance

Pharmaceutical Medicine

Volumn 24, Issue 5, 2010, Pages 281-288

  McNeil, John J ^a   Piccenna, Loretta ^a   Ronaldson, Kathlyn ^a   Ioannides Demos, Lisa L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Adverse drug reactions incidence; Adverse reaction monitoring; Postmarketing surveillance; Prescription event monitoring.

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; BIOLOGICAL PRODUCT; BOSENTAN; CLOZAPINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN;

AGRANULOCYTOSIS; DRUG COST; DRUG EFFICACY; DRUG REGISTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; HEMOPHILIA; HUMAN; INFECTION; MEDICAL RECORD; MORBIDITY; NOTE; PATIENT CARE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REGISTRATION; RISK BENEFIT ANALYSIS; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOEMBOLISM; THROMBOSIS;

EID: 77958477645     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.2165/11584450-000000000-00000     Document Type: Note

References (41)

1. McClellan M. Drug safety reform at the FDA: pendulum swing or systematic improvement? N Engl J Med 2007; 356: 1700-2
2. Kao DP. What can we learn from drug marketing efficiency? BMJ 2008; 337: a2591
3. Platt R, Wilson M, Chan A, et al. The new sentinel network: improving the evidence of medical-product safety. N Engl J Med 2009; 361: 645-7
4. European Medicines Agency. Public status reporton the implementation ofthe European risk management strategy, 2007 [online].Available from URL: http:// www.emea.europa.eu/pdfs/human/phv/16895407en.pdf [Accessed 2010 Aug 30]
5. European Medicines Agency. EU-ADR website [online]. Available from URL: http://www.euadr-project.org [Accessed 2010 Aug 30]
6. Sturkenboom MC, Kors J, D?az Acedo C, et al. EU-ADR: a European multifaceted approach to improving postmarketing surveillance of drugs. London: bmj.com. Rapid Response, 2009 Feb 26
7. FuruK, WettermarkB,AndersenM, etal. The Nordic countriesasacohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2009; 106: 86-94
8. Mackay FJ. Post-marketing studies: the work of the Drug Safety Research Unit. Drug Saf 1998; 19: 343-53
9. Fogg C, Kasliwal R, Shakir SA. Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study. Drug Saf 2009; 32 (3): 229-37
10. Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibu-tramine: results of prescription-event monitoring studies in England. Obesity 2007; 15 (11): 2712-22
11. Twaites BR, Wilton LV, Shakir SA. Safety of zafirlukast: results of a post-marketing surveillance study on 7976 patients in England. Drug Saf 2007; 30 (5): 419-29
12. Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009; 32 (6): 499-507
13. Clark DW, Harrison-Woolrych M. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions. Curr Drug Safety 2006; 1: 169-78
14. Agency for Healthcare Research and Quality. Registries for evaluating pa-tient outcomes: a user's guide, 2007 Apr [online]. Available from URL: http://www.effectivehealthcare.ahrq.gov/ehc/products/21/11/PatOutcomes. pdf [Accessed 2010 Mar 17].
15. Tanaka K, Morita Y, Kawabe E, et al. Drug use investigation (DUI) and prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf 2001; 10: 653-8
16. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997; 99: 765-73
17. Food and Drug Administration US. Department of Health & Human Service. Prescription Drug User Fee Act (PDUFA) IV. Drug safety five-year plan: draft 2008 Mar [online]. Available from URL: http://www.fda.gov/down loads/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm093946.pdf [Accessed 2010 Jun 16].
18. Committee for Medicinal Products for Human Use, European Medicines Agency. Guideline on risk management systems for medicinal products for human use. 2005. Nov [online]. Available from URL: http://www.emea.eur opa.eu/pdfs/human/euleg/9626805en.pdf [Accessed 2010 Jun 16].
19. Isbister J, Phillips L, Dunkley S, et al. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Hae-mostasis Register. J Intern Med 2008; 38 (3): 156-65
20. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-44
21. Keogh A, McNeil K, Williams TJ, et al. The bosentan patient registry: long-term survival in pulmonary arterial hypertension. Intern Med J. Epub 2009
22. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first pro-gression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26 (33): 5326-34
23. Australian Commission on Safety and Quality in Healthcare, NHMRC Centre for Research Excellencein Patient Safety (CREPS) at Monash University and the National E-Health Transition Authority (NEHTA). Operating principles and technical standards for Australian Clinical Quality Registries. 2008 Nov [online]. Available from URL: http://www.crepatientsafety.org.au/registries/ operating-principals-technical-standards-nov08.pdf [Accessed 2010 Mar 17].
24. Zink A, Askling J, Dixon WG, et al. European biologicals registers: metho-dology, selected results and perspectives. Ann Rheum Dis 2009; 68: 1240-6
25. Ray W. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158 (9): 915-20
26. Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 2005; 23 (5 Suppl. 39): S205-7
27. Kremers HM. Methods to analyze real-world databases and registries. Bull NYU Hosp Jt Dis 2009; 67: 193-7
28. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies. 2: assessing potential for confounding. BMJ 2005; 330: 960-2
29. Levine MN, Julian JA. Registries that show efficacy: good, but not good en-ough. J Clin Oncol 2008; 33: 5316-9
30. Kremer JM, Greenberg J. Interpreting registry-derived drug studies: does so-cietal context matter? Arthritis Rheum 2009; 60: 3155-7
31. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psych 1998; 59 Suppl. 3: 3-7
32. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine induced agranulo-cytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7
33. Locatelli F, Aljama P, Barany P, et al. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: where are we now and where do we go from here? Nephrol Dial Transplant 2004; 19: 288-93
34. Thomas A. Immunogenicity assessment of therapeutic proteins: strategy of RMP. Johnson & Johnson, BMWP/BWP workshop on immunogenicity: assessment of therapeutic proteins. London: EMEA, 2007 Sep 4 [online]. Available from URL: http://www.ema.europa.eu/pdfs/conferenceflyers/bmwp/ thomas.pdf [Accessed 2010 Mar 26]
35. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mor-tality in association with therapies for Crohn's Disease: TREAT Registry. Clin Gastroenterol Hepatol 2006; 4: 621-30
36. Dixon WG, Watson K, Lunt K, et al. Rates of serious infection including site-specific and bacterial intracellular infection in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 2368-76
37. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006; 65: 707-12
38. MitraB,Philips L,Cameron PA,et al. The safety of recombinant factor VIIa in cardiac surgery. Anaesth Intensive Care 2010; 38 (4): 671-7
39. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56: 1125-33
40. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64
41. Curtis JR, Martin C, Saag KG, et al. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. Arthritis Rheum 2007; 57: 343-6